Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.30
HAE's Cash to Debt is ranked higher than
54% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. HAE: 0.30 )
HAE' s 10-Year Cash to Debt Range
Min: 0.09   Max: 60.69
Current: 0.3

0.09
60.69
Equity to Asset 0.56
HAE's Equity to Asset is ranked higher than
65% of the 275 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. HAE: 0.56 )
HAE' s 10-Year Equity to Asset Range
Min: 0.52   Max: 0.84
Current: 0.56

0.52
0.84
Interest Coverage 4.33
HAE's Interest Coverage is ranked higher than
51% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.42 vs. HAE: 4.33 )
HAE' s 10-Year Interest Coverage Range
Min: 3.6   Max: 9999.99
Current: 4.33

3.6
9999.99
F-Score: 5
Z-Score: 3.18
M-Score: -2.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 4.41
HAE's Operating margin (%) is ranked higher than
68% of the 286 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. HAE: 4.41 )
HAE' s 10-Year Operating margin (%) Range
Min: 4.57   Max: 23.59
Current: 4.41

4.57
23.59
Net-margin (%) 3.24
HAE's Net-margin (%) is ranked higher than
69% of the 286 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.97 vs. HAE: 3.24 )
HAE' s 10-Year Net-margin (%) Range
Min: -8.68   Max: 16.46
Current: 3.24

-8.68
16.46
ROE (%) 3.70
HAE's ROE (%) is ranked higher than
67% of the 276 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.15 vs. HAE: 3.70 )
HAE' s 10-Year ROE (%) Range
Min: -11.81   Max: 17.5
Current: 3.7

-11.81
17.5
ROA (%) 2.04
HAE's ROA (%) is ranked higher than
69% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.87 vs. HAE: 2.04 )
HAE' s 10-Year ROA (%) Range
Min: -7.51   Max: 13.62
Current: 2.04

-7.51
13.62
ROC (Joel Greenblatt) (%) 7.53
HAE's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. HAE: 7.53 )
HAE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 7.77   Max: 57.49
Current: 7.53

7.77
57.49
Revenue Growth (%) 10.70
HAE's Revenue Growth (%) is ranked higher than
85% of the 261 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. HAE: 10.70 )
HAE' s 10-Year Revenue Growth (%) Range
Min: -2.5   Max: 15
Current: 10.7

-2.5
15
EBITDA Growth (%) -7.40
HAE's EBITDA Growth (%) is ranked higher than
63% of the 219 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. HAE: -7.40 )
HAE' s 10-Year EBITDA Growth (%) Range
Min: -56.2   Max: 106.5
Current: -7.4

-56.2
106.5
EPS Growth (%) -24.60
HAE's EPS Growth (%) is ranked higher than
55% of the 218 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. HAE: -24.60 )
HAE' s 10-Year EPS Growth (%) Range
Min: -74.3   Max: 141
Current: -24.6

-74.3
141
» HAE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

HAE Guru Trades in Q4 2013

Steven Cohen 19,006 sh (New)
James Barrow 958,209 sh (New)
Jean-Marie Eveillard 10,000 sh (+11.11%)
Chuck Royce Sold Out
Third Avenue Management Sold Out
Columbia Wanger Sold Out
Ken Fisher 147,995 sh (-12.56%)
Paul Tudor Jones 5,900 sh (-32.18%)
Jim Simons 26,100 sh (-89.01%)
» More
Q1 2014

HAE Guru Trades in Q1 2014

Robert Olstein 14,400 sh (New)
Joel Greenblatt 42,809 sh (New)
Jim Simons 254,226 sh (+874.05%)
Paul Tudor Jones 29,518 sh (+400.31%)
James Barrow 3,042,669 sh (+217.54%)
Steven Cohen 43,161 sh (+127.09%)
Jean-Marie Eveillard 10,000 sh (unchged)
Ken Fisher 147,445 sh (-0.37%)
» More
Q2 2014

HAE Guru Trades in Q2 2014

Ken Fisher 177,645 sh (+20.48%)
Robert Olstein Sold Out
Jean-Marie Eveillard Sold Out
James Barrow 2,926,524 sh (-3.82%)
Joel Greenblatt 38,590 sh (-9.86%)
Jim Simons 214,800 sh (-15.51%)
Paul Tudor Jones 10,100 sh (-65.78%)
» More
Q3 2014

HAE Guru Trades in Q3 2014

Ken Fisher 177,645 sh (unchged)
Paul Tudor Jones Sold Out
James Barrow 2,842,114 sh (-2.88%)
Joel Greenblatt 29,531 sh (-23.47%)
Jim Simons 36,700 sh (-82.91%)
» More
» Details

Insider Trades

Latest Guru Trades with HAE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Reduce -23.47%$34.1 - $37.1 $ 37.375%29531
Robert Olstein 2014-06-30 Sold Out 0.06%$30.36 - $35.62 $ 37.3712%0
Ken Fisher 2014-06-30 Add 20.48%$30.36 - $35.62 $ 37.3712%177645
Jean-Marie Eveillard 2014-06-30 Sold Out $30.36 - $35.62 $ 37.3712%0
James Barrow 2014-03-31 Add 217.54%0.1%$31.84 - $43.37 $ 37.37-3%3042669
Robert Olstein 2014-03-31 New Buy0.06%$31.84 - $43.37 $ 37.37-3%14400
Joel Greenblatt 2014-03-31 New Buy0.02%$31.84 - $43.37 $ 37.37-3%42809
James Barrow 2013-12-31 New Buy0.06%$38.87 - $43.83 $ 37.37-9%958209
Third Avenue Management 2013-12-31 Sold Out 0.03%$38.87 - $43.83 $ 37.37-9%0
Third Avenue Management 2013-06-30 Reduce -27.59%0.01%$37.75 - $42.71 $ 37.37-8%42000
Third Avenue Management 2013-03-31 Reduce -25.64%0.02%$40.78 - $44.44 $ 37.37-11%58000
Ken Fisher 2013-03-31 Add 26.97%$40.78 - $44.44 $ 37.37-11%166920
Meridian Funds 2012-12-31 Add 100%0.29%$38.92 - $41.38 $ 37.37-7%354600
Third Avenue Management 2012-12-31 Reduce -53.77%0.17%$38.92 - $41.38 $ 37.37-7%78000
Ken Fisher 2012-12-31 Add 104.06%0.01%$38.92 - $41.38 $ 37.37-7%131465
Jean-Marie Eveillard 2012-12-31 Add 100%$38.92 - $41.38 $ 37.37-7%8000
Third Avenue Management 2012-09-30 Reduce -49.31%0.29%$68.61 - $81.4 $ 37.37-50%168722
Meridian Funds 2012-09-30 Add 21.86%0.09%$68.61 - $81.4 $ 37.37-50%177300
Meridian Funds 2012-06-30 New Buy0.36%$66.79 - $73.87 $ 37.37-47%145500
Joel Greenblatt 2012-03-31 Sold Out 0.12%$61.85 - $70.45 $ 37.37-40%0
Ken Fisher 2012-03-31 Reduce -20.62%$61.85 - $70.45 $ 37.37-40%56025
Third Avenue Management 2011-12-31 Add 1017.81%0.42%$55.01 - $64.58 $ 37.37-37%296131
Joel Greenblatt 2011-09-30 Add 77.59%0.05%$56.03 - $69.18 $ 37.37-40%13062
Third Avenue Management 2011-09-30 New Buy0.04%$56.03 - $69.18 $ 37.37-40%26492
George Soros 2011-09-30 Sold Out 0.0046%$56.03 - $69.18 $ 37.37-40%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Haemonetics Corp

Meridian Funds Comments on Haemonetics - Aug 28, 2013

Haemonetics (HAE) is the market leader in blood management products for collection centers and hospitals. The company's equipment and related consumables allow collection centers to separate blood into the components of plasma, red cells and white cells. Hospital-based products include blood diagnostics, devices to salvage patient blood during surgery and software to manage blood supply. Earnings temporarily declined due to two product quality issues that management of Haemonetics has stated have been remedied. In our opinion, earnings growth may be expected to accelerate in the next few years as Haemonetics rolls out its automated whole blood collection solution to collection centers. Relative to the existing manual process, the company's automated solution speeds up the collection process and reduces discard rates. Cost and efficiency gains become more important to collection centers as hospitals better manage their blood supply. We believe the company is a compelling value at 12x our $3.50 estimate of earnings power.

From Meridian Funds' June 30, 2013 commentary.


Check out Meridian Funds latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 65.10
HAE's P/E(ttm) is ranked higher than
71% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 42.50 vs. HAE: 65.10 )
HAE' s 10-Year P/E(ttm) Range
Min: 17.15   Max: 110.8
Current: 65.1

17.15
110.8
P/B 2.30
HAE's P/B is ranked higher than
80% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.51 vs. HAE: 2.30 )
HAE' s 10-Year P/B Range
Min: 1.94   Max: 3.97
Current: 2.3

1.94
3.97
P/S 2.10
HAE's P/S is ranked higher than
78% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.92 vs. HAE: 2.10 )
HAE' s 10-Year P/S Range
Min: 1.57   Max: 3.59
Current: 2.1

1.57
3.59
PFCF 77.90
HAE's PFCF is ranked higher than
77% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 719.57 vs. HAE: 77.90 )
HAE' s 10-Year PFCF Range
Min: 10.25   Max: 130.83
Current: 77.9

10.25
130.83
EV-to-EBIT 53.78
HAE's EV-to-EBIT is ranked higher than
69% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.27 vs. HAE: 53.78 )
HAE' s 10-Year EV-to-EBIT Range
Min: 9.9   Max: 71.9
Current: 53.78

9.9
71.9
Shiller P/E 34.60
HAE's Shiller P/E is ranked higher than
85% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 398.57 vs. HAE: 34.60 )
HAE' s 10-Year Shiller P/E Range
Min: 21.83   Max: 46.76
Current: 34.6

21.83
46.76
Current Ratio 3.37
HAE's Current Ratio is ranked higher than
81% of the 275 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.72 vs. HAE: 3.37 )
HAE' s 10-Year Current Ratio Range
Min: 2.17   Max: 4.92
Current: 3.37

2.17
4.92
Quick Ratio 2.11
HAE's Quick Ratio is ranked higher than
75% of the 275 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. HAE: 2.11 )
HAE' s 10-Year Quick Ratio Range
Min: 1.53   Max: 4.22
Current: 2.11

1.53
4.22

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 8.50
HAE's Price/Tangible Book is ranked higher than
65% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.41 vs. HAE: 8.50 )
HAE' s 10-Year Price/Tangible Book Range
Min: 1.7   Max: 13.78
Current: 8.5

1.7
13.78
Price/DCF (Projected) 1.60
HAE's Price/DCF (Projected) is ranked higher than
85% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.87 vs. HAE: 1.60 )
HAE' s 10-Year Price/DCF (Projected) Range
Min: 1.13   Max: 2.88
Current: 1.6

1.13
2.88
Price/Median PS Value 0.90
HAE's Price/Median PS Value is ranked higher than
88% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.20 vs. HAE: 0.90 )
HAE' s 10-Year Price/Median PS Value Range
Min: 0.53   Max: 1.4
Current: 0.9

0.53
1.4
Price/Graham Number 4.90
HAE's Price/Graham Number is ranked higher than
74% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.72 vs. HAE: 4.90 )
HAE' s 10-Year Price/Graham Number Range
Min: 1.08   Max: 11.74
Current: 4.9

1.08
11.74
Earnings Yield (Greenblatt) 1.90
HAE's Earnings Yield (Greenblatt) is ranked higher than
67% of the 284 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.00 vs. HAE: 1.90 )
HAE' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 10.1
Current: 1.9

1.4
10.1
Forward Rate of Return (Yacktman) 0.22
HAE's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 247 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.17 vs. HAE: 0.22 )
HAE' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.1   Max: 24.4
Current: 0.22

0.1
24.4

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:HAZ.Germany
Haemonetics Corp is a healthcare company that provides blood management solutions to its customers. Its portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood supply chain, helps improve clinical outcomes and reduce costs for blood and plasma collectors, hospitals, and patients around the world. Its products and services help prevent a transfusion to a patient who does not need one and provide the right blood product, at the right time, in the right dose to the patient who does. It serves three markets: manufacturers of plasma derived pharmaceuticals, blood collectors, and hospitals. Its product categories include: Plasma, Blood Center, Hospital, and Software Solutions. Plasma includes plasma collection devices and consumables. Blood Center includes blood collection and processing devices and consumables. Hospital includes surgical blood salvage and blood demand diagnostic devices and consumables. Software Solutions includes information technology platforms and consulting services provided to all three markets. The products it manufactures and markets are subject to regulation by the Center of Biologics Evaluation and Research and the Center of Devices and Radiological Health of the United States Food and Drug Administration, and other non-United States regulatory bodies.
» More Articles for HAE

Headlines

Articles On GuruFocus.com
Meridian Contrarian Fund Second Quarter Commentary Sep 08 2014 
Guru Held Stocks Near Historical Low P/B Jul 22 2014 
The Olstein All Cap Value Fund’s 2014 First Quarter Letter to Shareholders Jul 22 2014 
This Blood Management Company Can Be A Safe Investment Jul 13 2014 
Meridian Funds Comments on Haemonetics Aug 28 2013 
Meridian Funds' Second Quarter 2013 Commentary Aug 28 2013 
Weeky CFO Sells Highlight: ADBE, HAE, WAGE, OVTI, ICPT Jun 24 2013 
Allscripts-Misys Reports 5 Insider Buys the Day Before Barclays Conference Mar 13 2013 
Weekly Guru Bargains Highlights: HAE, DLTR, QCOR, MTX, AMD Jan 21 2013 
Weekly Guru Bargains Highlights: CIG, ARO, NKE, DLTR, HAE Jan 13 2013 

More From Other Websites
Haemonetics to Present at the Jefferies 2014 Global Healthcare Conference Nov 11 2014
Haemonetics to Present at the Jefferies 2014 Global Healthcare Conference Nov 11 2014
HAEMONETICS CORP Financials Nov 11 2014
10-Q for Haemonetics Corp. Nov 06 2014
HAEMONETICS CORP Files SEC form 10-Q, Quarterly Report Nov 04 2014
Haemonetics Q2 Earnings Beat Estimates but Decline Y/Y Nov 04 2014
Haemonetics Corp Earnings Call scheduled for 8:00 am ET today Nov 03 2014
Q2 2015 Haemonetics Corp Earnings Release - Before Market Open Nov 03 2014
Haemonetics beats 2Q profit forecasts Nov 03 2014
Haemonetics beats 2Q profit forecasts Nov 03 2014
HAEMONETICS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 03 2014
Haemonetics Reports 2nd Quarter Fiscal 2015 Revenue of $228 Million and Adjusted EPS of $0.47;... Nov 03 2014
Is Haemonetics (HAE) Poised to Beat on Q2 Earnings? Oct 30 2014
3PEA International and Haemonetics Partner to Integrate PaySign Connect with Haemonetics’ Donor... Oct 21 2014
Haemonetics Sets Date for Second Quarter Fiscal Year 2015 Earnings Release: November 3, 2014 Oct 06 2014
Perrigo Sells Some Assets to Imago Pharmaceuticals Oct 03 2014
Data Intensity Fortifies Track Record of Success in Oracle EBS R12 Implementations and Upgrades Sep 23 2014
HAEMONETICS CORP Files SEC form 8-K, Change in Directors or Principal Officers Sep 22 2014
Haemonetics (HAE) Poised on Strong Q2, Optimistic Outlook Sep 19 2014
Insider Trading Alert - TUP, HAE And SNI Traded By Insiders Sep 03 2014
Haemonetics to Present at Morgan Stanley's Global Healthcare Conference Aug 22 2014
Haemonetics Tops Q1 Earnings and Revenues, Guidance Retained Aug 01 2014
Wall Street Transcript Interview with Christopher Clark, the CFO of Neovasc Inc. (NVCN) Aug 01 2014
HAEMONETICS CORP Files SEC form 10-Q, Quarterly Report Jul 31 2014
Haemonetics Provides Update on U.S. Whole Blood Supply Tender Mar 24 2014
Haemonetics Sets Date for Investor/Analyst Meeting - May 20, 2014 Feb 05 2014
Haemonetics Announces Signing of Supply Agreement with HemeXcel at J.P. Morgan Health Care... Jan 12 2014
Haemonetics Business Update at J.P. Morgan Health Care Conference Will Include Status of U.S. Whole... Jan 03 2014
Haemonetics to Present at the 32nd Annual J.P. Morgan Health Care Conference Jan 02 2014
Haemonetics Sets Date for Third Quarter Fiscal Year 2014 Earnings Release: January 27, 2014 Dec 20 2013

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK